Navigation Links
Experimental Drug Shows Promise for Bone Marrow Disorder
Date:9/15/2010

WEDNESDAY, Sept. 15 (HealthDay News) -- In ongoing early stage research, an experimental drug appears to go some distance toward reducing the tell-tale inflammatory impact of the deadly bone marrow disorder known as myelofibrosis.

Indications that the oral drug -- called INCB018424 -- shows promise are reported in the Sept. 16 issue of the New England Journal of Medicine.

"The problem with myelofibrosis is the lack of available therapies for patients; there are none approved for this disease today," study lead author Dr. Srdan Verstovsek, an associate professor at the M.D. Anderson Cancer Center's department of leukemia in Houston, said in a news release from the center.

"This experimental drug is the first to target one of the underlying abnormalities in the malignant cells that cause myelofibrosis," Verstovsek added. "It provides unprecedented reduction of enlarged spleens that are a central characteristic of the disease, and relieves pain, fatigue and other symptoms, improving quality of life."

For reasons as yet poorly understood, myelofibrosis occurs when aggressive bone marrow cells "scar" bone marrow, the soft, fatty tissue inside bones. The process so severely curtails the bone marrow's ability to produce blood cells that anemia results.

In turn, the liver and spleen attempt to take up the blood production slack, causing these organs to swell to painful proportions and impinging on the stomach and bowels. This prompts malnutrition, weight loss, fatigue, and a progressively debilitating loss of the ability to bend and move properly, according to background information in the news release.

An estimated 3,000 Americans are newly afflicted with the disease each year, with an average life expectancy of between five to seven years. There is no known cure or effective treatment, leaving doctors few resources for the alleviation of pain and suffering.

The drug currently being tested is designed to shut down the abnormal activity of JAK2 gene mutations, which have been found to be responsible for the over-growth of bone marrow cells, and have been linked to many cases of myelofibrosis.

The researchers initially began testing the drug in about 150 patients who had advanced-stage myelofibrosis or were newly diagnosed (in 2007) with high-intermediate or high-risk disease. Ongoing work will focus on 115 of these patients.

Verstovsek and his colleagues have so far found that one month after treatment with INCB018424, about half of the patients experienced a 50 percent reduction in symptom scores, and nearly 60 percent of these patients maintained this drop a half-year out.

Between 70 percent and 82 percent of the patients experienced a minimum of a 25 percent reduction in spleen size after taking the experimental drug for two months -- a drop that endured for more than a year.

And MRI scans revealed that by the six-month treatment mark, on average, patients achieved a reduction in spleen size of about one-third, with nearly half experiencing a spleen size shrinkage of 35 percent or more.

Improvement in the ability to exercise and average weight gains of about 15 to 20 pounds following one-year of treatment were also evident, the report indicated.

Even patients who did not have the JAK2 mutation that the drug was designed to attack seemed to benefit from the new treatment, the researchers said.

"This suggests that patients who do not have specific mutations still have a very active JAK signaling pathway and can benefit from JAK inhibition," Verstovsek said. "However, because the drug also inhibits normal JAK2, it can lead to low blood counts that can limit dosing."

Dr. Mark H. Kirschbaum, director of developmental therapeutics and acting chair of hematology at the Nevada Cancer Institute in Las Vegas, called the research "a first breakthrough" in the attempt to tackle myelofibrosis.

Kirschbaum cautioned, however, that researchers had initially held out hope that the drug under investigation might even have a more dramatic impact on symptoms, given the key role JAK2 mutations appear to play in development of the disease.

"But at least there was some palliation for a group of patients," Kirschbaum said. "And this certainly represents an encouraging first step towards more definitive treatment for this nasty disorder."

The study was funded by Incyte Corporation, which developed the JAK2-inhibitor, and Verstovsek has received research funding from the company. The research is ongoing in the United States, Canada, Australia and Europe.

More information

For more on myelofibrosis, visit the U.S. National Library of Medicine.

-- Alan Mozes

SOURCES: M.D. Anderson Cancer Center, news release, Sept. 15, 2010; Mark H. Kirschbaum, M.D., director, developmental therapeutics, and acting chair, hematology, Nevada Cancer Institute, Las Vegas


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental TB Test Called Fast and Accurate
2. Experimental treatments for cocaine addiction may prevent relapse
3. Experimental obesity drug avoids brain effects that troubled predecessors
4. Experimental nonsteroidal treatment of asthma shows promise
5. Experimental targeted therapy shows early promise against medulloblastomas
6. Experimental Vaccine Shields Monkeys Against Ebola
7. Experimental Drug Offers Hope for Cystic Fibrosis Patients
8. Report shows federal poverty guidelines leave states seniors destitute
9. Study shows tranquil scenes have positive impact on brain
10. Targeted agent shows promise for chronic lymphoid leukemia
11. Research shows unemployment programs lacking for people with disabilities
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Shows Promise for Bone Marrow Disorder
(Date:4/21/2017)... ... April 21, 2017 , ... During April 21-23, Super-Sod will join ... This festival offers entertainment for everyone — from the avid gardener to the landscape ... very high quality event held in a grand venue, and we are certainly looking ...
(Date:4/21/2017)... ... April 21, 2017 , ... A new medical study ... replacement patients; post-operative recovery just might be even better than they imagined. Researchers ... osteoarthritis following surgery: 262 patients under 65 and 103 patients over 75. The ...
(Date:4/21/2017)... ... April 21, 2017 , ... National pest management association survey conducted in 2010 ... bug infestations over the 5-year period. In 2015 10% or US$750 million per annum ... bug infested properties. , The health and economic consequences of bed bug ...
(Date:4/21/2017)... ... April 21, 2017 , ... In a recently released ... a summer camp for kids in Dana Point, parents are challenged to find ways ... writers caution parents to find age appropriate activities that both reinforce their child’s learning ...
(Date:4/20/2017)... Carolina (PRWEB) , ... April 20, 2017 , ... ... of the fourth book in its growing library. The Greener The Grass, ... Quarterback and alumnus of Walnut Grove High School, shares a deeply personal, hard-earned ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 The ... anticipated to showcase a healthy CAGR during the forecast period ... product type in the global digital mobile X-Ray devices market, ... 2,000 Mn in 2017, expanding at a CAGR of 7% ... create absolute $ opportunity of more than US$ 100 Mn ...
(Date:4/19/2017)... , April 19, 2017 Global Prostate ... report on the prostate cancer therapeutics market analyzes ... market. Increasing prevalence of prostate cancer, launch of ... the development of new drugs & therapeutic biological ... drug due to lesser side effects are some ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology: